Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis …
M Shiomi, T Ito, T Tsukada, Y Tsujita, H Horikoshi - Atherosclerosis, 1999 - Elsevier
We examined whether improving insulin resistance augments the antiatherosclerotic effect
of LDL reduction. Since WHHL rabbits show hyperinsulinemia and insulin resistance, we
administered troglitazone (100 mg/kg), an insulin action enhancer, pravastatin sodium (50
mg/kg), an HMG–CoA reductase inhibitor, and a combination of both drugs to 2-month-old
WHHL rabbits for 32 weeks. As compared to the control, total cholesterol levels in the
plasma and LDL were decreased significantly by≈ 20% in the pravastatin and combination …
of LDL reduction. Since WHHL rabbits show hyperinsulinemia and insulin resistance, we
administered troglitazone (100 mg/kg), an insulin action enhancer, pravastatin sodium (50
mg/kg), an HMG–CoA reductase inhibitor, and a combination of both drugs to 2-month-old
WHHL rabbits for 32 weeks. As compared to the control, total cholesterol levels in the
plasma and LDL were decreased significantly by≈ 20% in the pravastatin and combination …
